Lead Author: Richard Bogan, MD, FCCP, FAASM, Associate Clinical Professor at the University of South Carolina School of Medicine in Columbia, SC NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced seven presentations, including two featured oral plenary sessions, on AXS-12 and solriamfetol, at SLEEP 2025, the 39th annual meeting of the Associated Profess ...

SYMBRAVO represents a novel multi-mechanistic approach to treating migraine that addresses multiple pathways underlying a migraine attack SYMBRAVO On My Side offers comprehensive patient support services including access and prescription drug support NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that SYMBRAVO (meloxicam and rizatriptan) is now avai ...

Axsome Therapeutics (AXSM) FY Conference June 09, 2025 02:40 PM ET Speaker0 Great. Hi. Thanks for joining us today. My name is Mark Jacobson. I'm the Chief Operating Officer at Axsome Therapeutics. And thank you to Goldman Sachs for hosting us today. So I may be making forward looking statements, we'd invite you to review our disclosures and summary of risks and uncertainties, which you can find in our filings with the Securities and Exchange Commission. So Axsome Therapeutics, our mission is to develop and ...

Axsome Therapeutics (AXSM) 2025 Conference June 05, 2025 02:35 PM ET Speaker0 started with the next session. I'm Andrew Tsai, senior biotech analyst at Jefferies. Thanks for tuning in. And it's my pleasure to have Mark Jacobsen, Chief Operating Officer next to me from Axsome. Welcome. Speaker1 Hey, thanks. Thanks for having us, Andrew. Speaker0 Yeah, you got it. So maybe briefly, introduction about Axsome, what you're working on, what your strategy is, and then maybe talk about some of these near term catal ...

Although fundamental investing wisdom tells us to "buy low," it may still be worthwhile to purchase shares of top companies following significant runs. Any point can be considered low -- even after massive gains -- provided there is plenty of upside left. That brings us to Summit Therapeutics (SMMT -4.83%) and Axsome Therapeutics (AXSM -1.68%), two biotechs that have been on fire over the past few years. Still, it's not too late to invest in these drugmakers. Here's the rundown.1. Summit TherapeuticsSummit ...

It has been about a month since the last earnings report for Axsome Therapeutics (AXSM) . Shares have lost about 1.8% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Axsome due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.How Have Estimates Been Moving Since Then?It ...

Axsome Therapeutics (AXSM) FY Conference June 03, 2025 11:40 AM ET Speaker0 To the the William Blair forty fifth Annual Growth Stock Conference. My name is Miles Minto. I'm a senior biotech analyst here at the firm. I cover the neurosciences and genetic medicines, and Axsome has been a day one coverage company for me. So early two thousand seventeen before before the Ascend data actually was when picked up coverage there. You know, obviously a bona fide growth story with a Vality well underway, launch of a ...

Details of the presentations are as follows: AUVELITY Title: Initiating Dextromethorphan 45 mg - Bupropion 105 mg (AUVELITY) in Patients with Major Depressive Disorder (MDD): Expert Panel Consensus Recommendations Lead Author: Anita Clayton, MD, Wilford W. Spradlin Professor and Chair of Psychiatry & Neurobehavioral Sciences and Professor of Clinical Obstetrics & Gynecology at the University of Virginia Presentation Date and Time: Wednesday, May 28, 11:15 a.m. - 1 p.m. Mountain Standard Time Session Name: P ...

operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to ...

纪要涉及的公司 Axsome Therapeutics (AXSM) 纪要提到的核心观点和论据 1. **宏观经济影响** - 公司业务多元化，大部分业务在美国，受宏观因素影响小 [4][7] - Ovelity和SINBRAVO仅在美国商业销售，不受最惠国定价影响；NOSI在少数美国以外国家销售，影响极小 [5] - 除Sunosi的IP位于欧洲外，其他项目IP均在美国，目前Sunosi不受影响；关税对成本影响不大 [6][7] 2. **AUVELITY产品情况** - 产品增长良好，15%用于一线治疗，35%用于二线治疗，超55%为单药治疗，体现差异化疗效和耐受性 [8][9] - 目前年销售额约4亿美元，一季度扩大销售团队，已在NBRx产生影响，预计持续拉动TRx增长 [9][10] - 预计改善市场准入，包括增加商业渠道覆盖人数和提高覆盖质量；考虑开展全国DTC营销活动 [10][11] - 预计OVELITY在重度抑郁症（MDD）领域峰值销售额为10 - 30亿美元 [12] 3. **销售团队拓展** - 2024年一季度增加100名代表，开始进入初级保健市场；2025年一季度增加40名客户经理，销售团队达300人，可增加拜访频率和覆盖更多初级保健目标 [14][15] 4. **长期销售指导** - 15 - 30亿美元的销售指导受市场覆盖扩大、初级保健市场拓展、定价动态等因素影响，目前处于早期阶段，公司对实现目标有信心 [17][18] 5. **与Teva的和解** - Teva是唯一的首仿申请者，专利有效期至2043年，协议规定其可在2039年进入市场 [19][20] 6. **阿尔茨海默病激越症研究** - 四项研究中三项结果积极，正在整理数据，计划在第三季度提交sNDA申请 [21][22] - FDA要求两项充分且良好控制的研究，公司已有三项积极研究和独立的长期安全数据库，对提交的申请有信心 [24][25] - 预计峰值销售额与抑郁症产品相似，为15 - 30亿美元，现有团队和基础设施有利于产品获批后的推广 [32] 7. **Symbravo产品** - 将于下个月推出，销售团队约100人，正在进行培训和入职，将专注于头痛专科医生和头痛中心 [34][35] - 偏头痛产品的推出策略与抑郁症产品不同，将采取数据驱动、有纪律的方式，考虑患者储蓄和支持措施 [36][37] 8. **Sunosi产品研究** - ADHD成人研究数据积极，下一步进行儿科研究，预计2025年开展，FDA要求一项成人和一项儿科青少年试验 [39][41] - 抑郁症伴发作性睡病（EDS）研究将针对重度抑郁症伴过度日间嗜睡患者，预计需要两项研究 [44][45] 9. **公司盈利情况** - 公司今年预计营收5 - 6亿美元，一季度末有3000万美元资金，有望实现现金流转正 [46] 其他重要但是可能被忽略的内容 - 阿尔茨海默病激越症研究中，FDA要求独立的ICH安全数据库和随机对照安全数据，公司从两项研究中获得了相关数据 [26] - 偏头痛产品的支付方管理与抑郁症不同，几乎每个支付方都要求预先授权和至少一种通用曲坦类药物治疗步骤 [36][37]